Key facts
- AWCT’s last known valuation is $30.0M (Nov 2023).
- It has raised $20.5M; the latest was Later Stage VC in Jun 2025.
- Notable investors include WI Harper Group, Taiwania Capital.
- Status: Privately Held (backing).
Investors
2- ·The complete investor list — 2 names
- ·Watchlist + deal alerts for AWCT
- ·The full record, as it builds
Funding rounds
No funding rounds for AWCT are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About AWCT
Developer of healthcare technology intended to restructure the treatment of diseases and disorders without drugs, implants, or surgery. The company's technology activates innate repair mechanisms in tissue to replace cells and repair damage from wounds and disease, enabling doctors to match the effectiveness of surgery with a non-invasive, minimal-risk treatment.
- Sector
- Healthcare
- HQ
- Los Angeles, CA, United States
- Founded
- 2014
- Employees
- 9
- Website
- awct.us/
- Ownership
- Privately Held (backing)
AWCT doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in AWCT shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on AWCT in its N-PORT filings yet. We sweep new filings monthly.